MMT Home Banner

Magnolia Medical Technologies

Inventors of the Initial Specimen Diversion Technology

UH Cost-Benefit Released

Newly Released: Cost-Benefit Analysis

A University of Houston published study concludes hospitals can save up to $367 per blood culture.

MMT Home CEU

A Partnership Inspired by Evidence

We are pleased to announce our partnership with the Center for Phlebotomy Education. Discover new evidence-based education, training and earn CEU credit.

Vizient Innovation Contract Background

Vizient Innovative Technology Contract

Steripath Gen2 is designated an Innovative Technology, offering unique benefits over other products available in the market today.

SteriPath Gen2 showing diverted contaminants
Steripath Logo

Partnering with you to significantly reduce blood culture contamination

The Steripath® Gen2 Initial Specimen Diversion Device (ISDD®) has been shown in independent clinical trials to significantly reduce preventable blood culture contamination and false-positive results for bloodstream infections and sepsis.

Blood Culture Contamination

The Challenge, Impact and Solution

events:

CE Course by Center of Phlebotomy Education

Earn Credits Today
Dennis J. Ernst MT (ASCP), NCPT (NCCT) | Credit Hours: 1.0

Our Vision

Through our focus on specimen integrity and testing accuracy, we aim to:

ELIMINATE
MILLION
patient misdiagnoses and ensuing mistreatments
SAVE
lives at minimum
CREATE OVER
BILLION
in direct cost savings for our hospital customers

The Scientist
Behind Steripath

Transforming Medical Care for Providers and Patients

We are focused on improving critical processes and technologies to deliver unprecedented efficiency, effectiveness, and optimal patient outcomes.  With over 42 patents in our portfolio, we’ll keep innovating until we change the status quo.